Boston Scientific Co. (NYSE:BSX) Shares Sold by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 2.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 318,303 shares of the medical equipment provider’s stock after selling 6,356 shares during the quarter. Boston Scientific accounts for approximately 0.8% of Dana Investment Advisors Inc.’s investment portfolio, making the stock its 20th largest position. Dana Investment Advisors Inc.’s holdings in Boston Scientific were worth $24,513,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BSX. Triad Wealth Partners LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. First Foundation Advisors bought a new position in shares of Boston Scientific in the first quarter valued at $25,000. Eagle Bay Advisors LLC lifted its position in shares of Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 309 shares during the last quarter. Andra AP fonden bought a new stake in shares of Boston Scientific during the 2nd quarter worth $29,000. Finally, Lynx Investment Advisory acquired a new position in shares of Boston Scientific in the 2nd quarter worth $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on BSX shares. Robert W. Baird increased their price target on Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. TD Cowen boosted their price target on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Citigroup increased their target price on Boston Scientific from $90.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price target on shares of Boston Scientific in a research report on Thursday, July 25th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $86.65.

Boston Scientific Stock Up 0.5 %

Shares of BSX stock opened at $83.80 on Tuesday. The stock’s 50 day simple moving average is $79.44 and its 200 day simple moving average is $75.43. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $84.89. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The company has a market capitalization of $122.94 billion, a price-to-earnings ratio of 70.42, a PEG ratio of 2.78 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The business had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. Boston Scientific’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the business posted $0.53 EPS. As a group, research analysts predict that Boston Scientific Co. will post 2.4 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the transaction, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at $3,061,135.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.